End-of-day quote
Other stock markets
|
||
- SEK | - |
27/05 | Sweden’s IRLAB Therapeutics Names New CEO | MT |
27/05 | IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 | CI |
Sales 2024 * | 65.65M 6.23M 520M | Sales 2025 * | 138M 13.11M 1.09B | Capitalization | 734M 69.67M 5.82B |
---|---|---|---|---|---|
Net income 2024 * | -111M -10.54M -880M | Net income 2025 * | -27M -2.56M -214M | EV / Sales 2024 * | 11 x |
Net cash position 2024 * | 11.93M 1.13M 94.53M | Net Debt 2025 * | 256M 24.35M 2.03B | EV / Sales 2025 * | 7.17 x |
P/E ratio 2024 * |
-4.59
x | P/E ratio 2025 * |
-3.95
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.48% |
Latest transcript on IRLAB Therapeutics AB
Managers | Title | Age | Since |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 01/13/01 |
Chief Executive Officer | 71 | 06/17/06 | |
Nicholas Waters
FOU | Founder | 62 | 01/13/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 01/16/01 |
Rein Piir
BRD | Director/Board Member | 66 | 01/16/01 |
Chairman | 66 | 01/19/01 |
1st Jan change | Capi. | |
---|---|---|
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
+11.88% | 216B | |
-0.78% | 219B | |
+5.90% | 164B |